CorVel Corporation — Form 10-Q Summary
Business context and reporting period
CorVel provides medical cost containment and managed care services, including network solutions and patient management, to insurers, third-party administrators, government entities and self-insured employers. It reports one managed-care operating segment.
The filing covers the quarter and six months ended September 30, 2017 (fiscal 2018 second quarter), compared with the corresponding 2016 periods. This differs from the request metadata’s “2016 Q2.” The interim financial statements are unaudited.
Key financial results
| Metric | Three months ended Sep. 30, 2017 | Year-over-year change | Six months ended Sep. 30, 2017 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $136.4 million | +6.4% | $274.0 million | +6.8% |
| Gross profit / margin | $25.8 million / 18.9% | Gross profit −0.6%; margin 20.2% prior year | $54.5 million / 19.9% | Gross profit +5.9%; margin 20.1% prior year |
| Income before taxes | $12.1 million | +7.2% | $26.2 million | +12.2% |
| Net income | $8.4 million | +20.7% | $17.2 million | +18.9% |
| Diluted EPS | $0.44 | +$0.09 | $0.90 | +$0.17 |
| Operating cash flow | Not separately presented for the quarter | — | $30.6 million | $20.5 million prior year |
Quarterly revenue growth came primarily from patient management, up 8.7%, particularly TPA services; case management for non-TPA customers declined. Network solutions revenue rose 3.4%. For the six-month period, patient management revenue rose 7.9% and network solutions 5.3%. In the quarter, cost of revenue grew faster than revenue, reflecting higher salaries, pharmacy costs and benefits; gross margin contracted. Lower general and administrative costs and a lower effective tax rate helped lift quarterly net income. The tax rate decline was attributed partly to excess tax benefits from exercised options, and management said it did not expect the lower rate to continue.
Cash, debt, liquidity and capital allocation
- Cash and cash equivalents were $38.1 million at September 30, 2017, up $9.5 million from March 31, 2017. Working capital was $46.6 million; current assets were $148.3 million and current liabilities $101.7 million.
- Six-month operating cash flow was $30.6 million; investing cash use was $11.4 million, primarily capital purchases; financing cash use was $9.6 million, mainly share repurchases. Capital expenditures were $11.4 million. Operating cash flow less capital expenditures was approximately $19.2 million.
- No debt or revolving loans were outstanding. A renewed revolving credit facility provides up to $10 million and expires in September 2018. The company reported compliance with its covenants. Letters of credit totaled $4.5 million and, according to the filing, do not reduce borrowing availability.
- Six-month repurchases totaled 249,245 shares for $11.2 million, at an average $44.88 per share; no shares were repurchased during the quarter. Lower weighted-average shares contributed to EPS growth.
- CorVel agreed to buy a 32,000-square-foot building in Milwaukie, Oregon, for approximately $5.8 million, expects to use existing cash, and expects closing in 2018. The contractual-obligations table lists $5.79 million due within one year.
Outlook, commentary, risks and unusual items
- Management said cash from operations, option exercises and the credit facility should be adequate for obligations, share repurchases, new services and development for at least the next 12 months. The filing provides no formal revenue or earnings guidance.
- Management noted a long-term decline in U.S. workplace injury rates, which could reduce claims and medical spending available for review. It also cited fewer working days in the third fiscal quarter as a potential seasonal factor.
- Key risks include declining workers’ compensation claims, competition and customer insourcing, pricing pressure, customer losses or consolidation, labor availability and costs, regulatory changes, litigation and liability exposure, and data security or service interruptions.
- Ordinary-course litigation was not expected by management to result in material payments. The company reported a $444,000 impairment of its private-equity investment during the six months. It reported no indicators of impairment for goodwill or long-lived assets at September 30.
- Operating leases totaled $54.5 million in disclosed contractual obligations. The company said it had no off-balance-sheet arrangements as defined by SEC rules; it described customary indemnification obligations for which material liabilities had not been recorded.
- Management said standard-contract analysis indicated the new revenue-recognition standard was not expected to have a significant impact, but the effect on non-standard contracts remained undetermined. The lease standard’s impact was still under evaluation.
Important facts for investors to verify
- Confirm the reporting-period mismatch: this is the September 30, 2017 quarter, not a 2016 Q2 filing.
- Track whether TPA-led growth continues and whether margins recover as lower-margin TPA services, case-management trends, wage costs and pharmacy costs affect results.
- Assess the sustainability of cash conversion and capital spending, and the effect of the planned $5.8 million property purchase and continued share repurchases on liquidity.
- Monitor the credit-facility renewal and covenant compliance, especially as the facility was due to expire in September 2018.
- Review future effective tax rates: the filing attributes part of the period’s lower rate to unusually high option-exercise tax benefits.
- Check subsequent disclosures on the private-equity investment impairment, non-standard customer contracts under the revenue standard, and self-insurance estimates and legal contingencies.